

# ICOTYDE™ (icotrokinra) Prior Authorization Checklist

## Reminders and Tips for Completing Prior Authorizations for Your Patients

Each health plan may have its own unique prior authorization (PA) form with varying requirements. It is important to gather necessary information during the patient's first appointment to ensure an effective process with minimal delays.

### Essentials for Approval

- **Diagnosis must match FDA indication for ICOTYDE**
  - Diagnosis must be moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg
  - Patients must be candidates for systemic therapy or phototherapy even if not on treatment
- **All information the payer policy requires**, including notes of previously used medicine, response to therapy (patient has tried and failed topicals, phototherapy, and/or DMARDs), and other medical record documentation, including tuberculosis (TB) test, if required.

Be sure to have the following information on hand to help you complete the PA form:



#### Patient Information

##### Patient Insurance Information

- Copy of the patient's prescription card (front and back)
- Copy of the patient's health insurance card (front and back)

##### Patient Contact Information (phone and email preferred)



#### Patient Diagnosis/Clinical Information

##### ICD-10 Code

- L40.0 (Psoriasis vulgaris)

##### Supporting Clinical Information

- Lab Results and Dates
- Photographs of Affected Areas
- Psoriasis Area and Severity Index (PASI)/ Investigator's Global Assessment (IGA) Score
- Percent Body Surface Area Coverage
- Disease Severity

##### Patient Medication History (including treatments from previous healthcare providers):

- Duration of Therapy (including conventional therapy)
- Clinical Response
- Allergy
- Strength
- Schedule

Codes are supplied for informational purposes only and represent no statement, promise, or guarantee that reimbursement will be made. Information provided is not intended to increase or maximize reimbursement.

### SELECTED IMPORTANT SAFETY INFORMATION

Avoid treatment with ICOTYDE™ in patients with any clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue ICOTYDE until the infection resolves. Consider evaluating for tuberculosis (TB) prior to initiating treatment with ICOTYDE based on clinical judgement. Monitor patients for signs and symptoms of active TB during and after treatment. Avoid use of live vaccines during treatment. Please see related and other Important Safety Information on the next page.





## Other Resources

### Letter of Medical Necessity

- Visit [JNJwithMe.com/hcp/icotyde](https://www.jnjwithme.com/hcp/icotyde) and look under the Forms and Guides drop-down menu for a sample letter
- For expedited requests, adequate information should be provided to support the urgent nature of the request

### Product Full Prescribing Information, Peer-Reviewed Journal Articles, or Clinical Guidelines

#### Patient Authorization

- Patient signature may be required for patient support program enrollment. Please encourage your patients to complete and submit this form



## Once you have made the decision to prescribe ICOTYDE ICOTYDE withMe provides free support to help your patients start and stay on treatment

### ICOTYDE withMe support includes:

- Access and affordability support
- Office educational resources
- A dedicated Nurse Guide\*
- Specialty pharmacy enhanced services†

Visit [JNJwithMe.com/hcp/icotyde](https://www.jnjwithme.com/hcp/icotyde)

Or call 844-4withMe (844-494-8463), Monday–Friday, 8:00 AM to 8:00 PM ET

The patient support and resources provided by ICOTYDE withMe are not intended to give medical advice, replace a treatment plan from the patient's healthcare provider, offer services that would normally be performed by the provider's office, or serve as a reason to prescribe ICOTYDE.

\*Nurse Guides do not provide medical advice.

†Enhanced services provided by each specialty pharmacy may vary.

## INDICATION

ICOTYDE™ (icetokina) 200 mg is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS

#### Infections

Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ICOTYDE. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection and/or is not responding to standard therapy, monitor the patient closely and discontinue ICOTYDE until the infection resolves.

#### Tuberculosis (TB)

Consider evaluating for TB prior to initiating treatment with ICOTYDE based on clinical judgement. Consider anti-TB therapy prior to initiating ICOTYDE in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment. Avoid administering ICOTYDE to patients with active TB.

#### Immunizations

Avoid use of live vaccines in patients during treatment with ICOTYDE. Medications that interact with the immune system may increase the risk of the infection following administration of live vaccines. Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.

### ADVERSE REACTIONS

Most common adverse reactions (≥1%) are headache, nausea, cough, fungal infection, and fatigue. The adverse reactions observed in pediatric patients were consistent with the most common adverse reactions (≥1%) observed in the overall population.

### USE IN SPECIFIC POPULATIONS

#### Moderate or Severe Renal Impairment

Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min.

#### Pregnancy

The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ICOTYDE.

Provide the [Medication Guide](#) to your patients and encourage discussion.

cp-564098v1